Bioequivalence Study of Carvedilol Tablets USP 12.5 mg Under Fasting Condition
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open Label, balanced, two-treatment, two-period, two-sequence, single
dose, cross over pivotal study. The purpose of this study is to assess the bioequivalence
between Test Product and the corresponding Reference Product under fasting condition in
normal, healthy, adult, human subjects.